Lymphocyte‑Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis
Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort